New York State Common Retirement Fund raised its holdings in shares of Glaukos Corp (NYSE:GKOS) by 24.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 141,923 shares of the medical instruments supplier’s stock after purchasing an additional 28,330 shares during the period. New York State Common Retirement Fund owned 0.41% of Glaukos worth $4,683,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. C WorldWide Group Holding A S increased its position in shares of Glaukos by 13.0% during the third quarter. C WorldWide Group Holding A S now owns 291,425 shares of the medical instruments supplier’s stock valued at $9,617,000 after acquiring an additional 33,594 shares in the last quarter. Wrapmanager Inc. bought a new stake in shares of Glaukos during the third quarter valued at approximately $307,000. FDx Advisors Inc. bought a new stake in shares of Glaukos during the third quarter valued at approximately $421,000. Shaker Investments LLC OH increased its position in shares of Glaukos by 6.3% during the third quarter. Shaker Investments LLC OH now owns 47,025 shares of the medical instruments supplier’s stock valued at $1,552,000 after acquiring an additional 2,800 shares in the last quarter. Finally, OLD National Bancorp IN bought a new stake in shares of Glaukos during the third quarter valued at approximately $387,000. 99.23% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently weighed in on GKOS. Cantor Fitzgerald set a $48.00 price target on shares of Glaukos and gave the company a “buy” rating in a research report on Wednesday, December 27th. BMO Capital Markets reaffirmed a “buy” rating on shares of Glaukos in a research report on Monday, December 11th. Zacks Investment Research raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, November 13th. Stephens reaffirmed an “overweight” rating and issued a $40.00 target price (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. Finally, BidaskClub downgraded shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $44.86.
In other news, CFO Joseph E. Gilliam bought 2,100 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The shares were bought at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the purchase, the chief financial officer now owns 102,100 shares in the company, valued at $2,434,064. The acquisition was disclosed in a document filed with the Securities Exchange Commission, which is accessible through the SEC website. 16.40% of the stock is currently owned by insiders.
Glaukos Corp (NYSE:GKOS) opened at $28.20 on Thursday. Glaukos Corp has a one year low of $23.08 and a one year high of $52.49. The firm has a market cap of $974.74 and a price-to-earnings ratio of -940.00.
Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06. Glaukos had a net margin of 3.28% and a return on equity of 4.12%. The company had revenue of $40.41 million for the quarter, compared to analysts’ expectations of $38.69 million. During the same quarter in the previous year, the company earned $0.03 EPS. Glaukos’s revenue for the quarter was up 36.6% on a year-over-year basis. analysts expect that Glaukos Corp will post -0.03 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Boosts Stake in Glaukos Corp (NYSE:GKOS)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was illegally copied and republished in violation of US international copyright and trademark laws. The original version of this story can be read at https://stocknewstimes.com/2018/01/11/new-york-state-common-retirement-fund-has-4-68-million-stake-in-glaukos-corporation-gkos.html.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News Ratings for Glaukos Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Glaukos and related companies with MarketBeat.com’s FREE daily email newsletter.